SCHEMBL3963760

SCHEMBL3963760

CNC(=O)c1cccc2sc(-c3nc(NCCCN4CCNC(C)C4)ncc3C)cc12

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 1/20 0.36
SELE P16581 1/20 0.36
TYRO3 Q06418 3/20 0.35
MERTK Q12866 3/20 0.35
GAS6 Q14393 3/20 0.35
FLT3 P36888 2/20 0.35
FGFR1 P11362 7/20 0.35
LCK P06239 2/20 0.34
MET P08581 4/20 0.33
ALK Q9UM73 3/20 0.33
STAT6 P42226 1/20 0.33
MAPK14 Q16539 1/20 0.32
EGFR P00533 1/20 0.32
SRC P12931 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
XIAP P98170 1/20 0.32
BIRC2 Q13490 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963752 1.00 ICAM1 (0.36) ICAM1SELETYRO3MERTKGAS6
SCHEMBL3966411 0.93 TYRO3 (0.39) TYRO3MERTKGAS6FLT3FGFR1
SCHEMBL3958625 0.92 FGFR1 (0.38) TYRO3MERTKGAS6FLT3FGFR1
SCHEMBL3970368 0.90 ICAM1 (0.39) ICAM1SELEFGFR1LCKEGFR
SCHEMBL3970362 0.90 ICAM1 (0.39) ICAM1SELEFGFR1LCKEGFR
Hydrochloric Acid SCHEMBL4093503 0.89 ICAM1 (0.38) ICAM1SELEFGFR1LCKEGFR
Hydrochloric Acid SCHEMBL4093496 0.89 ICAM1 (0.38) ICAM1SELEFGFR1LCKEGFR
SCHEMBL3964461 0.88 ICAM1 (0.46) ICAM1SELEFGFR1LCKEGFR
Hydrochloric Acid SCHEMBL3969902 0.87 ICAM1 (0.46) ICAM1SELEFGFR1LCKEGFR
SCHEMBL3964622 0.85 FGFR1 (0.40) TYRO3MERTKGAS6FLT3FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG ICAM1 597/4885SELE 4065/4885TYRO3 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.